The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis. Nearly 9 million people in the United States are living with plaque psoriasis ...

WESTLAKE VILLAGE, Calif. - The U.S. Food and Drug Administration (FDA) has approved ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adults ...

Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with ...

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis. Nearly 9 million people in the United States are living with plaque psoriasis ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...